$156 Million is the total value of Asymmetry Capital Management, L.P.'s 34 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 64.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $8,559,000 | -20.9% | 155,232 | -9.4% | 5.50% | -33.6% |
| GH | Sell | GUARDANT HEALTH INC | $7,698,000 | -1.2% | 68,863 | -28.3% | 4.95% | -17.1% |
| NSTG | Sell | NANOSTRING TECHNOLOGIES INC | $7,208,000 | +11.8% | 161,253 | -26.6% | 4.63% | -6.2% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $6,979,000 | -35.9% | 93,308 | -46.0% | 4.49% | -46.2% |
| SAGE | Sell | SAGE THERAPEUTICS INC | $6,262,000 | -23.7% | 102,462 | -48.1% | 4.02% | -35.9% |
| TXG | Sell | 10X GENOMICS INC-CLASS A | $5,425,000 | +19.5% | 43,512 | -14.4% | 3.49% | +0.3% |
| BMYRT | Sell | BRISTOL-MYERS SQUIBB-CVRrts | $3,511,000 | -72.4% | 1,560,327 | -56.1% | 2.26% | -76.9% |
| ATRS | Sell | ANTARES PHARMA INC | $3,225,000 | -9.7% | 1,194,530 | -8.1% | 2.07% | -24.3% |
| AVDL | Sell | AVADEL PHARMACEUTICALS PLCadr | $2,625,000 | -39.1% | 520,830 | -2.4% | 1.69% | -48.9% |
| RAPT | Exit | RAPT THERAPEUTICS INC | $0 | – | -34,652 | -100.0% | -0.77% | – |
| NXTC | Exit | NEXTCURE INC | $0 | – | -48,456 | -100.0% | -0.80% | – |
| UBX | Exit | UNITY BIOTECHNOLOGY INC | $0 | – | -120,179 | -100.0% | -0.80% | – |
| GRTS | Exit | GRITSTONE ONCOLOGY INC | $0 | – | -222,817 | -100.0% | -1.13% | – |
| MRNS | Exit | MARINUS PHARMACEUTICALS INC | $0 | – | -586,243 | -100.0% | -1.14% | – |
| BLUE | Exit | BLUEBIRD BIO INC | $0 | – | -25,000 | -100.0% | -1.17% | – |
| MGTA | Exit | MAGENTA THERAPEUTICS INC | $0 | – | -211,063 | -100.0% | -1.21% | – |
| AIMT | Exit | AIMMUNE THERAPEUTICS INC | $0 | – | -100,544 | -100.0% | -1.29% | – |
| LPTX | Exit | LEAP THERAPEUTICS INC | $0 | – | -900,733 | -100.0% | -1.44% | – |
| TWST | Exit | TWIST BIOSCIENCE CORP | $0 | – | -53,344 | -100.0% | -1.85% | – |
| BNTX | Exit | BIONTECH SEadr | $0 | – | -38,626 | -100.0% | -1.98% | – |
| BIO | Exit | BIO-RAD LABORATORIES-A | $0 | – | -6,434 | -100.0% | -2.23% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -234,753 | -100.0% | -2.71% | – |
| PTCT | Exit | PTC THERAPEUTICS | $0 | – | -73,708 | -100.0% | -2.86% | – |
| CNC | Exit | CENTENE CORP | $0 | – | -77,402 | -100.0% | -3.77% | – |
| MNTA | Exit | MOMENTA PHARMACEUTICALS INC | $0 | – | -159,197 | -100.0% | -4.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.